145 related articles for article (PubMed ID: 34392146)
1. Dose-dependent effects of anthocyanin supplementation on platelet function in subjects with dyslipidemia: A randomized clinical trial.
Tian Z; Li K; Fan D; Zhao Y; Gao X; Ma X; Xu L; Shi Y; Ya F; Zou J; Wang P; Mao Y; Ling W; Yang Y
EBioMedicine; 2021 Aug; 70():103533. PubMed ID: 34392146
[TBL] [Abstract][Full Text] [Related]
2. Dose-dependent reductions in plasma ceramides after anthocyanin supplementation are associated with improvements in plasma lipids and cholesterol efflux capacity in dyslipidemia: A randomized controlled trial.
Zhao Y; Xu H; Tian Z; Wang X; Xu L; Li K; Gao X; Fan D; Ma X; Ling W; Yang Y
Clin Nutr; 2021 Apr; 40(4):1871-1878. PubMed ID: 33131908
[TBL] [Abstract][Full Text] [Related]
3. The effect of anthocyanin supplementation in modulating platelet function in sedentary population: a randomised, double-blind, placebo-controlled, cross-over trial.
Thompson K; Hosking H; Pederick W; Singh I; Santhakumar AB
Br J Nutr; 2017 Sep; 118(5):368-374. PubMed ID: 28901892
[TBL] [Abstract][Full Text] [Related]
4. Anthocyanin supplementation improves anti-oxidative and anti-inflammatory capacity in a dose-response manner in subjects with dyslipidemia.
Zhang H; Xu Z; Zhao H; Wang X; Pang J; Li Q; Yang Y; Ling W
Redox Biol; 2020 May; 32():101474. PubMed ID: 32179241
[TBL] [Abstract][Full Text] [Related]
5. Purified anthocyanin supplementation reduces dyslipidemia, enhances antioxidant capacity, and prevents insulin resistance in diabetic patients.
Li D; Zhang Y; Liu Y; Sun R; Xia M
J Nutr; 2015 Apr; 145(4):742-8. PubMed ID: 25833778
[TBL] [Abstract][Full Text] [Related]
6. Anthocyanin supplementation at different doses improves cholesterol efflux capacity in subjects with dyslipidemia-a randomized controlled trial.
Xu Z; Xie J; Zhang H; Pang J; Li Q; Wang X; Xu H; Sun X; Zhao H; Yang Y; Ling W
Eur J Clin Nutr; 2021 Feb; 75(2):345-354. PubMed ID: 32317748
[TBL] [Abstract][Full Text] [Related]
7. Pharmacodynamic efficacy, clinical safety, and outcomes after prolonged platelet Glycoprotein IIb/IIIa receptor blockade with oral xemilofiban: results of a multicenter, placebo-controlled, randomized trial.
Kereiakes DJ; Kleiman NS; Ferguson JJ; Masud AR; Broderick TM; Abbottsmith CW; Runyon JP; Anderson LC; Anders RJ; Dreiling RJ; Hantsbarger GL; Bryzinski B; Topol EJ
Circulation; 1998 Sep; 98(13):1268-78. PubMed ID: 9751674
[TBL] [Abstract][Full Text] [Related]
8. Anthocyanin supplementation improves serum LDL- and HDL-cholesterol concentrations associated with the inhibition of cholesteryl ester transfer protein in dyslipidemic subjects.
Qin Y; Xia M; Ma J; Hao Y; Liu J; Mou H; Cao L; Ling W
Am J Clin Nutr; 2009 Sep; 90(3):485-92. PubMed ID: 19640950
[TBL] [Abstract][Full Text] [Related]
9. Anthocyanins in berries exhibited anti-atherogenicity and antiplatelet activities in a metabolic syndrome population.
Aboonabi A; Meyer RR; Gaiz A; Singh I
Nutr Res; 2020 Apr; 76():82-93. PubMed ID: 32217379
[TBL] [Abstract][Full Text] [Related]
10. Sustained platelet glycoprotein IIb/IIIa blockade with oral xemilofiban in 170 patients after coronary stent deployment.
Kereiakes DJ; Kleiman N; Ferguson JJ; Runyon JP; Broderick TM; Higby NA; Martin LH; Hantsbarger G; McDonald S; Anders RJ
Circulation; 1997 Aug; 96(4):1117-21. PubMed ID: 9286938
[TBL] [Abstract][Full Text] [Related]
11. Inhaled nitric oxide inhibits human platelet aggregation, P-selectin expression, and fibrinogen binding in vitro and in vivo.
Gries A; Bode C; Peter K; Herr A; Böhrer H; Motsch J; Martin E
Circulation; 1998 Apr; 97(15):1481-7. PubMed ID: 9576429
[TBL] [Abstract][Full Text] [Related]
12. Assessment of in vitro Effects of Anthocyanins on Platelet Function.
Gaiz A; Kundur AR; Colson N; Shibeeb S; Singh I
Altern Ther Health Med; 2020 Jan; 26(1):12-17. PubMed ID: 31634878
[TBL] [Abstract][Full Text] [Related]
13. Comparison of Aggregometry with Flow Cytometry for the Assessment of Agonists´-Induced Platelet Reactivity in Patients on Dual Antiplatelet Therapy.
Gremmel T; Koppensteiner R; Panzer S
PLoS One; 2015; 10(6):e0129666. PubMed ID: 26058047
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of dose-related effects of aspirin on platelet function: results from the Aspirin-Induced Platelet Effect (ASPECT) study.
Gurbel PA; Bliden KP; DiChiara J; Newcomer J; Weng W; Neerchal NK; Gesheff T; Chaganti SK; Etherington A; Tantry US
Circulation; 2007 Jun; 115(25):3156-64. PubMed ID: 17562955
[TBL] [Abstract][Full Text] [Related]
15. Effects of anthocyanins and their gut metabolites on adenosine diphosphate-induced platelet activation and their aggregation with monocytes and neutrophils.
Krga I; Vidovic N; Milenkovic D; Konic-Ristic A; Stojanovic F; Morand C; Glibetic M
Arch Biochem Biophys; 2018 May; 645():34-41. PubMed ID: 29555206
[TBL] [Abstract][Full Text] [Related]
16. Incomplete inhibition of platelet aggregation and glycoprotein IIb-IIIa receptor blockade by abciximab: importance of internal pool of glycoprotein IIb-IIIa receptors.
Gawaz M; Ruf A; Pogatsa-Murray G; Dickfeld T; Rüdiger S; Taubitz W; Fischer J; Müller I; Meier D; Patscheke H; Schömig A
Thromb Haemost; 2000 Jun; 83(6):915-22. PubMed ID: 10896249
[TBL] [Abstract][Full Text] [Related]
17. Ticagrelor Inhibits Toll-Like and Protease-Activated Receptor Mediated Platelet Activation in Acute Coronary Syndromes.
Wadowski PP; Weikert C; Pultar J; Lee S; Eichelberger B; Koppensteiner R; Lang IM; Panzer S; Gremmel T
Cardiovasc Drugs Ther; 2020 Feb; 34(1):53-63. PubMed ID: 32062795
[TBL] [Abstract][Full Text] [Related]
18. Antagonism of the GPIIb/IIIa receptor with the nonpeptidic molecule BIBU52: inhibition of platelet aggregation in vitro and antithrombotic efficacy in vivo.
Guth BD; Seewaldt-Becker E; Himmelsbach F; Weisenberger H; Müller TH
J Cardiovasc Pharmacol; 1997 Aug; 30(2):261-72. PubMed ID: 9269956
[TBL] [Abstract][Full Text] [Related]
19. MK-383 (L-700,462), a selective nonpeptide platelet glycoprotein IIb/IIIa antagonist, is active in man.
Peerlinck K; De Lepeleire I; Goldberg M; Farrell D; Barrett J; Hand E; Panebianco D; Deckmyn H; Vermylen J; Arnout J
Circulation; 1993 Oct; 88(4 Pt 1):1512-7. PubMed ID: 8403299
[TBL] [Abstract][Full Text] [Related]
20. Anthocyanin Supplementation Alleviates Antithrombotic Risk by Inhibiting Platelet Activity in Humans.
Gaiz A; Kundur AR; Nikbakht E; Vugic L; Colson N; Shibeeb S; Singh I
Altern Ther Health Med; 2022 Feb; 28(2):44-49. PubMed ID: 33789251
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
